Ohio State Navbar

Sign In

Joseph Kitzmiller, MD, PhD, FCP

Positions

NIH Translational Scholar in Pharmacogenom​ics LINK
 
Assistant Professor

Joseph Kitzmiller, M.D., Ph.D.

College of Medicine, Department of Biological Chemistry & Pharmacology

College of Engineering, Department of Biomedical Engineering

Associate Director

OSUMC Center For Pharmacogenomics LINK

Expert Educator

College of Medicine: Lead, Serve, Inspire LINK

Director

OSU Fellowship Training Program in Clinical Pharmacology & Pharmacogenomics LINK
 
 
 

Office/Lab

5086/5084 Graves Hall, 333 W. 10th Avenue
Columbus, OH 43210
Phone: (614) 292-8438

 

Education

MS, PhD - College of Engineering, The Ohio State University
MD - College of Medicine, The Ohio State University
Internship - Internal Medicine, The Ohio State University
Fellowship - Clinical Pharmacology, The Ohio State University

Research Interests & Extramural Funding:

Translational Medicine, Pharmacogenomics, Pharmacoanalytic Methodology, Clinical Pharmacology, Research Ethics, and Drug Development; Cardiology, Pain and Psychology-related Pharmacology.
 
National Institutes of Health - Translational Candidate-Gene Studies of Statin Myopathy. NIMHD R01 (2017-2022). Grants.gov # 12284723. PI: Kitzmiller. Co-I: Binkley, Wang, McDougle.
 
National Institutes of Health - Genetics Influences on Statin Response. NIMHD L32 (2012-2020). Grants.gov # 10797968. PI: Kitzmiller.
 
American Heart Association - Racial disparities in heart failure clinical outcomes: discovery of genetic markers for high-risk African-Americans. (2014-2016). PI: Luzum. Co-I: Kitzmiller, Sadee.
 
National Institutes of Health - Statin Pharmacogenomics: A multi-gene PK-PD modeling approach. NIGMS K23 (2011-2016). Grants.gov # 10797968. PI: Kitzmiller. Co-I: Sadee, Jackson.
  

Recent Publications

Luzum JA, Sweet KM, Binkley PF, Schmidlen TJ, Jarvis JP, Christman MF, Sadee W, Kitzmiller JP. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. Pharmaceutical Research 2017; 34(8):1615-1625. 

Mukherjee C, Sweet KM, Luzum JA, Abdel-Rasoul M, Christman MF, Kitzmiller JP. Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. Personalized Medicine 2017; doi.org/10.2217/pme-2017-0022.

Di Minno A, Ravani A, Spadarella G, Sansaro D, Amato M, Tremoli E, Kitzmiller JP, Frigerio B. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Reviews 2017; 31(4):193-203.

Patel SJ, Kemper KJ, Kitzmiller JP. Physician perspectives on education, training, and implementation of complementary and alternative medicine. Advances in Medical Education and Practice 2017; 8:499-503.  

Kitzmiller JP. Luzum JA, Dauk A, Krauss RM, Medina MW. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clinical Translational Science 2017; 10(3):172-177.

Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics Personalized Medicine 2016; 9:97–106.     

Sardo CL, Kitzmiller JP, Apseloff G, Harris RB, Roe DJ, Stoner GD, and ET Jacobs.  An Open-label, Randomized Crossover Trial of Lyophilized Black Raspberries on Postprandial Inflammation in Older, Obese Males.  American Journal of Therapeutics 2016; 23(1): 86-91.   

Kitzmiller JP, Talameh JA, Isackson PJ, Changxing MA, Medina MW, Dauki AM, Mikulik EB, Ochs-Balcom HM, Vladutiu GD. GATM polymorphism associated with the risk for statin-induced myopathy not replicated in case-control analysis of 715 dyslipidemic individuals. Cell Metabolism 2015; 21(4):622-7.​

Luzum JA, Theusch E, Taylor KD, Wang A, Sadee W, Binkley PF, Krauss RM, Medina MW, Kitzmiller JP. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. Journal of Cardiovascular Pharmacology 2015;  66(1):80-85.

Kitzmiller JP, Barnett CJ, Steiner NS, Stoicea N, Kamar N, Luzum JA, Mikulik E, Bergese SD. Buprenorphine: Revisiting the Efficacy of Transdermal Delivery System. Therapeutic Delivery 2015; 6(4):419-22.

Wang J, Talameh JA, Phelps MA, Kitzmiller JP. A liquid chromatography-tandem mass spectrometry assay for the simultaneous quantificati​on of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma. Journal of Chromatography B 2015; 984:18–25.
 
Kitzmiller JP, Talameh JA, Baldassarre D, Krauss RM, Medina MLW. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the Cholesterol and Pharmacogenetics study cohort. Pharmacogenetics and Genomics 2014; 24(10):486-591.
 
Talameh JT, Kitzmiller JP. Pharmacogenetics of Statin-Induced Myopathy: A focused review of the clinical translation of pharmacokinetic genetic variants. Pharmacogenomics and Pharmacoproteomics 2014; 5:2-10.
 
Korbel L, George M, Kitzmiller JP. Clinically-Relevant Pharmacogenomic Testing in Pediatric Practice. Clinical Pediatrics 2014; 53:831-8.
 
Kitzmiller JP, Phelps MA, Neidecker MV, Apseloff G. Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly-accredited interdisciplinary training program at the Ohio State University. Advances in Medical Education and Practice 2014; 5;191-6.
 
Sardo CL, Kitzmiller JP, Apseloff G, Harris RB, Roe DJ, Stoner GD, and ET Jacobs. An open-label, randomized crossover trial of lyophilized black raspberries on postprandial inflammation in older, obese males. American Journal of Therapeutics ​2013; August 26 EPub ahead of print.
 
George M, Haasz M, Coronado A, Salhanick S, Korbel L, Kitzmiller JP. Acute dyskinesia, myoclonus, and akathisa in an adolescent male abusing quetiapine via nasal insufflations: a case study. BMC Pediatrics 2013; 13:187.
 
Kitzmiller JP, Binkley PF, Pandey Sr, Suhy AM, Baldassarre D, Hartmann K. Statin pharmacogenomics: Pursuing biomarkers for predicting clinical outcomes. Discovery Medicine 2013; 16(86) 45-53.
 
Kitzmiller JP, Foraker RE, Rose KM. Lipid-lowering pharmacotherapy and socioeconomic status: Atherosclerosis risk in communities (ARIC) surveillance study. BMC Public Health 2013; 13:488.
 

Apseloff G, Kitzmiller JP, Tishler CL. Credibility and comprehension of healthy volunteers in lengthy inpatient drug studies. American Journal of Therapeutics 2013; 20(3):257-260.

Baldassarre D, Amato M, Frigerio B, Columbo G, Binkley PF, Pandey SR, Suhy AM, Hartmann K, Kitzmiller JP. Pharmacogenomic biomarkers for the prediction of statins efficacy and safety. Arteriosclerosi 2013; 4:23-35.

Kitzmiller JP, Sullivan DM, Phelps MA, Wang D, Sadee W. CYP3A4/5 combined genotype analysis for predicting statin Dose requirement for optimal lipid control. Drug Metabolism & Drug Interaction 2013; 28(1):59-63.
 
Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci SV, Apseloff G, Kitzmiller JP, Harris SC. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. Journal of Pain Symptom Management 2013; 46:65-75.